Is Hemant Surgical overvalued or undervalued?

As of 25 August 2025, the valuation grade for Hemant Surgical has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 36.60, an EV to EBITDA ratio of 32.10, and a ROE of 14.82%. In comparison to its peers, Max Healthcare is considered very expensive with a PE of 98.51, while Apollo Hospitals is attractive with a PE of 71.67, highlighting that Hemant Surgical is relatively more reasonably priced within the healthcare services sector. Despite the fair valuation, Hemant Surgical has shown impressive stock performance, with a year-to-date return of 125.83%, significantly outpacing the Sensex's 4.48% return during the same period. This strong performance may suggest investor confidence, but the current ratios indicate that the company is not undervalued at this time.